Received May 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | 945665 | IM / RA |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | N/A | LX4484 | IM / RA |
Patient received her PCV-20 and Heplisav-B vaccines on 4/30/25; both immunizations administered to right deltoid per patient request. No reactions during post-vaccine 15-minute monitoring. Patient has no allergies, and confirmed that she had no prior known reactions to vaccines. Patient returned on 5/7/25 for another previously scheduled appointment, and reported that she had some redness/swelling at the injection site starting on 4/30/25 until Saturday, 5/3/25. Patient also reported having rash, itchiness, tiredness, and nausea (without vomiting) during this time period. Patient stated that she took Claritin, which helped her symptoms. Injection site still appeared a little red on 5/7/25. Reaction reported to the patient's PCP. Per MD, patient can continue to take Claritin as needed, with no other interventions needed at this time. Patient will be following up with PCP on 5/21/25; provider will discuss vaccine reactions with patient prior to ordering any additional doses of Heplisav-B, as it is unknown whether patient reaction to Heplisav-B vaccine, PCV-20 vaccine, or both.
None